The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Open accessAbstract
First-generation immune checkpoint inhibitors, including anti-CTLA-4 and anti-programmed death 1 (anti-PD-1) antibodies, have led to major clinical progress, yet resistance frequently leads to treatment failure. Thus, new targets acting on T cells are needed. CD33-related sialic acid-binding immunoglobulin-like lectins (Siglecs) are pattern-recognition immune receptors binding to a range of sialoglycan ligands, which appear to function as self-associated molecular patterns (SAMPs) that suppress autoimmune responses. Siglecs are expressed at very low levels on normal T cells, and these receptors were not until recently considered as interesting targets on T cells for cancer immunotherapy. Here, we show an upregulation of Siglecs, including Siglec-9, on tumor-infiltrating T cells from non-small cell lung cancer (NSCLC), colorectal, and ovarian cancer patients. Siglec-9-expressing T cells coexpressed several inhibitory receptors, including PD-1. Targeting of the sialoglycan-SAMP/Siglec pathway in vitro and in vivo resulted in increased anticancer immunity. T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer. Our data identify the sialoglycan-SAMP/Siglec pathway as a potential target for improving T cell activation for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 7×
“Cancer immunotherapy and, in particular, checkpoint blockade with inhibitors of the PD-1/PD-L1/L2 axis and CTLA-4 are now routinely used in daily oncological practice (1, 47).”
InfluentialThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
Mogensen, T. H. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-08 · Cited by 3,111
Sterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031
Self-citationSiglec-mediated regulation of immune cell function in disease
Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3737 · Cited by 1,122
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933 · cited 6×
“A recent analysis of chromatin states in murine and human TILs from melanoma and NSCLC patients demonstrated a subpopulation within PD-1 hi TILs that had a relatively higher expression of CD5 and lower expression of CD38 and CD101 and that showed a greater potential for reprogrammability and reactivation (31).”
InfluentialCao, X. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.8 · Cited by 665
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Complexity of Danger: The Diverse Nature of Damage-associated Molecular Patterns
Schaefer, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.619304 · Cited by 622
Wang, C., Thudium, K. B., Han, M., Wang, X.-T., Huang, H., Feingersh, D., Garcia, C., Wu, Y., Kuhne, M., Srinivasan, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0040 · Cited by 601
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Self-citationGlycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
Hudak, J. E., Canham, S. M., & Bertozzi, C. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1388 · Cited by 485
The tumour glyco-code as a novel immune checkpoint for immunotherapy
RodrÍguez, E., Schetters, S. T. T., & van Kooyk, Y. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.3 · Cited by 473
Sialic acids in cancer biology and immunity
Pearce, O. M. T., & Läubli, H. (2016) · Glycobiology · doi:10.1093/glycob/cwv097 · Cited by 470 · cited 2×
“patterns’ (SAMPs) by binding to CD33-related sialic acid-binding immunoglobulin-like lectins (CD33rSiglecs) (8, 9), a family of receptors on immune cells containing intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIM) (10-13).”
Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer
Wang, Y., McKay, J. D., Rafnar, T., Wang, Z., Timofeeva, M. N., Broderick, P., Zong, X., Laplana, M., Wei, Y., Han, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3002 · Cited by 454
Self-citationJandus, C., Boligan, K. F., Chijioke, O., Liu, H., Dahlhaus, M., Démoulins, T., Schneider, C., Wehrli, M., Hunger, R. E., Baerlocher, G. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65899 · Cited by 439
Self-citationCarlin, A. F., Uchiyama, S., Chang, Y.-C., Lewis, A. L., Nizet, V., & Varki, A. (2009) · Blood · doi:10.1182/blood-2008-11-187302 · Cited by 401
Self-citationThommen, D. S., Schreiner, J., Müller, P., Herzig, P., Roller, A., Belousov, A., Umana, P., Pisa, P., Klein, C., Bacac, M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0097 · Cited by 395
Self-citationBeatson, R., Tajadura-Ortega, V., Achkova, D., Picco, G., Tsourouktsoglou, T.-D., Klausing, S., Hillier, M., Maher, J., Noll, T., Crocker, P. R., et al. (2016) · Nature Immunology · doi:10.1038/ni.3552 · Cited by 378
Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 366
Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer
Rabinovich, G. A., & Croci, D. O. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.004 · Cited by 338
Varki, A. (2011) · Glycobiology · doi:10.1093/glycob/cwr087 · Cited by 263
Self-citationLegat, A., Speiser, D. E., Pircher, H., Zehn, D., & Fuertes Marraco, S. A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00455 · Cited by 250
Self-citationLäubli, H., Pearce, O. M. T., Schwarz, F., Siddiqui, S. S., Deng, L., Stanczak, M. A., Deng, L., Verhagen, A., Secrest, P., Lusk, C., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409580111 · Cited by 228
Self-citationLoss of Siglec expression on T lymphocytes during human evolution
Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P., & Varki, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510484103 · Cited by 204
Self-citationNegative Regulation of T Cell Receptor Signaling by Siglec-7 (p70/AIRM) and Siglec-9
Ikehara, Y., Ikehara, S. K., & Paulson, J. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403538200 · Cited by 203
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10
Bandala-Sanchez, E., Zhang, Y., Reinwald, S., Dromey, J. A., Lee, B.-H., Qian, J., Böhmer, R. M., & Harrison, L. C. (2013) · Nature Immunology · doi:10.1038/ni.2610 · Cited by 198
Carlin, A. F., Chang, Y.-C., Areschoug, T., Lindahl, G., Hurtado-Ziola, N., King, C. C., Varki, A., & Nizet, V. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090691 · Cited by 169
Self-citationToll-like receptors and immune regulation: implications for cancer therapy
Wang, R.-F., Miyahara, Y., & Wang, H. Y. (2008) · Oncogene · doi:10.1038/sj.onc.1210906 · Cited by 164
Chang, Y., Olson, J., Beasley, F. C., Tung, C., Zhang, J., Crocker, P. R., Varki, A. P., & Nizet, V. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003846 · Cited by 147
Self-citationThe interplay between Siglecs and sialylated pathogens
Chang, Y.-C., & Nizet, V. (2014) · Glycobiology · doi:10.1093/glycob/cwu067 · Cited by 145
Laubli, H. P., Alisson‐Silva, F., Stanczak, M. A., Siddiqui, S. S., Deng, L., Verhagen, A., Varki, N. M., & Varki, A. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.593129 · Cited by 129
Self-citationPerdicchio, M., Cornelissen, L. A. M., Streng‐Ouwehand, I., Engels, S., Verstege, M. I., Boon, L., Geerts, D., van Kooyk, Y., & Unger, W. W. J. (2016) · Oncotarget · doi:10.18632/oncotarget.6822 · Cited by 119
Yu, H., Gonzalez-Gil, A., Wei, Y., Fernandes, S. M., Porell, R. N., Vajn, K., Paulson, J. C., Nycholat, C. M., & Schnaar, R. L. (2017) · Glycobiology · doi:10.1093/glycob/cwx026 · Cited by 119
CD33‐related siglecs as potential modulators of inflammatory responses
Crocker, P. R., McMillan, S. J., & Richards, H. E. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06449.x · Cited by 102
Pröpster, J. M., Yang, F., Rabbani, S., Ernst, B., Allain, F. H. ‐., & Schubert, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602214113 · Cited by 96
Paired Siglec receptors generate opposite inflammatory responses to a human‐specific pathogen
Schwarz, F., Landig, C. S., Siddiqui, S. S., Secundino, I., Olson, J., Varki, N. M., Nizet, V., & Varki, A. P. (2017) · The EMBO Journal · doi:10.15252/embj.201695581 · Cited by 86
Self-citationPadler‐Karavani, V., Hurtado‐Ziola, N., Chang, Y., Sonnenburg, J. L., Ronagh, A., Yu, H., Verhagen, A., Nizet, V., Chen, X., Varki, N. M., et al. (2013) · The FASEB Journal · doi:10.1096/fj.13-241497 · Cited by 85
Self-citationCohen, M., Elkabets, M., Perlmutter, M., Porgador, A., Voronov, E., Apte, R. N., & Lichtenstein, R. G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001635 · Cited by 75
Nitschke, L. (2014) · Glycobiology · doi:10.1093/glycob/cwu066 · Cited by 64
Siglec-G represses DAMP-mediated effects on T cells
Toubai, T., Rossi, C., Oravecz-Wilson, K. I., Zajac, C. K., Liu, C., Braun, T. W., Fujiwara, H., Wu, J. J., Sun, Y., Brabbs, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92293 · Cited by 45
Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency
Ishii, T., Angata, T., Wan, E. S., Cho, M. H., Motegi, T., Gao, C., Ohtsubo, K., Kitazume, S., Gemma, A., Paré, P. D., et al. (2016) · Respirology · doi:10.1111/resp.12952 · Cited by 33
Soto, P. C., Karris, M., Spina, C. A., Richman, D. D., & Varki, A. P. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0951-7 · Cited by 16
Self-citation
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Small RNAs are modified with N-glycans and displayed on the surface of living cells
Flynn, R. A., Pedram, K., Malaker, S. A., Batista, P. J., Smith, B. A. H., Johnson, A. G., George, B. M., Majzoub, K., Villalta, P. W., Carette, J. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.023 · Cited by 633
Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
Mereiter, S., Balmaña, M., Campos, D., Gomes, J., & Reis, C. A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.006 · Cited by 565
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Smith, B. A. H., & Bertozzi, C. R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00093-1 · Cited by 500
Metadata
- Authors
- Stanczak, M. A., Siddiqui, S. S., Trefny, M. P., Thommen, D. S., Boligan, K. F., von Gunten, S., Tzankov, A., Tietze, L., Lardinois, D., Heinzelmann-Schwarz, V., von Bergwelt-Baildon, M., Zhang, W., Lenz, H.-J., Han, Y., Amos, C. I., Syedbasha, M., Egli, A., Stenner, F., Speiser, D. E., Varki, A., Zippelius, A., & Läubli, H.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-24
- Volume
- 128
- Issue
- 11
- Pages
- 4912-4923
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2888330968
- Cited by
- 296
- References
- 49
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.